This article will address the topic of PTI-1, which has aroused great interest in the academic and scientific community in recent years. PTI-1 is a topic widely addressed in scientific literature and has aroused the interest of researchers from various disciplines. Throughout this article, different perspectives and approaches related to PTI-1 will be analyzed, with the aim of offering a comprehensive and updated vision on this topic. Additionally, the practical and theoretical implications of PTI-1 will be examined, as well as possible avenues for future research in this field.
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C21H29N3S |
Molar mass | 355.54 g·mol−1 |
3D model (JSmol) | |
| |
|
PTI-1 (SGT-48) is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4]